8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jul 28, 2010)

Filed July 28, 2010For Securities:VRTX

Summary

This 8-K filing from Vertex Pharmaceuticals (VRTX) on July 28, 2010, primarily announces the release of the company's financial results for the quarter ended June 30, 2010. The key information for investors is contained within the press release, attached as Exhibit 99.1, which details the company's operational and financial performance for the period. While the 8-K itself doesn't provide the detailed financial figures, it directs investors to the attached press release for these crucial updates. Investors should review the referenced press release for comprehensive insights into Vertex's revenue, earnings per share, any significant product updates, pipeline advancements, or strategic developments that were discussed in relation to the second quarter of 2010. The filing serves as the official notification of the earnings release and ensures public accessibility to the company's financial condition and results of operations as of that date.

Key Highlights

  • 1Vertex Pharmaceuticals (VRTX) filed an 8-K on July 28, 2010, to report its financial results for the quarter ended June 30, 2010.
  • 2The filing incorporates by reference a press release (Exhibit 99.1) dated July 28, 2010, containing the detailed financial results.
  • 3Investors are directed to the press release for specific information on revenue, earnings, and other financial performance metrics for Q2 2010.
  • 4The 8-K itself serves as a notification of the earnings release, not a detailed presentation of the financial figures.
  • 5The information in the press release is subject to standard SEC disclaimers regarding forward-looking statements and liability under Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report that Vertex Pharmaceuticals released its financial results for the quarter ended June 30, 2010, on July 28, 2010. The detailed financial information is provided in an attached press release.

The actual financial results are contained within the press release dated July 28, 2010, which is attached to this 8-K filing as Exhibit 99.1. You will need to refer to that exhibit for specific figures on revenue, earnings, and other operational details.

No, the 8-K filing itself does not contain the specific financial numbers. It only announces that a press release with these details has been issued and incorporates that press release by reference. Investors must consult Exhibit 99.1 (the press release) for the actual financial data.

The disclaimer indicates that the information furnished in the press release (Exhibit 99.1) is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means Vertex Pharmaceuticals may not be subject to the same level of liability for any misstatements or omissions in that information as it would be for information that is formally 'filed' with the SEC. However, it can still be incorporated into other SEC filings.